Differential liver function at cessation of atezolizumab-bevacizumab versus lenvatinib in HCC: a multicenter, propensity-score matched comparative study

BackgroundAtezolizumab+bevacizumab (AB) and lenvatinib have been proposed as first-line treatment options for patients with advanced hepatocellular carcinoma (HCC), but comparative efficacy and associated factors are controversial.Materials and methodsThis real-world multicenter study analysed patie...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Ji Won Han, Pil Soo Sung, Jae-Sung Yoo, Hee Sun Cho, Soon Kyu Lee, Hyun Yang, Ji Hoon Kim, Heechul Nam, Hae Lim Lee, Hee Yeon Kim, Sung Won Lee, Do Seon Song, Myeong Jun Song, Jung Hyun Kwon, Chang Wook Kim, Si Hyun Bae, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon
Format:	Artigo
Język:	Inglês
Wydane:	Frontiers Media S.A. 2024-02-01
Seria:	Frontiers in Oncology
Hasła przedmiotowe:	HCC atezolizumab plus bevacizumab lenvatinib residual liver function survival
Dostęp online:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1372007/full
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!